Seattle Genetics (SGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (68)	4/29/2005 11:14:55 AM
From: keokalani'nui	Read Replies (2) of 161

Because the company is mortgaging a promising technical platform that requires only modest capital and no clinical development expertise to fund a couple very questionable very expensive clinical antibody programs. By analogy, as I once argued years ago, MEDX's and CAT's shareholders would have been far better off if the proprietary drug develpoment and antibody generation platforms were separate. Contrast for example, CRXL, which basically killed its proprietary antibody program in order to concentrate on licensing. As an alternative, I would like to see sgen kill at least its first two antibody programs--or have them hire a qualified outside expert to review them and report to an independent committee of the Board. And then of course publish the findings in the Annual Report. Do you disagree?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next